Loading
Hepatocellular Carcinoma Treatment and Prognosis / Cancer Cells and Metastasis · Journal article
Journal of Translational Medicine · September 9, 2026
Raises a question worth testing. It does not answer one.
This is a conceptual review proposing that c-MET signaling in lung cancer shapes the tumor microenvironment through spatial, metabolic, and immune mechanisms, and that static genomic measures do not capture functional MET dependency. The authors hypothesize that multidimensional biomarker frameworks and combination therapies targeting MET with immunomodulation or metabolic intervention may overcome resistance, but provide no new empirical evidence or clinical trial data to support these claims.
Narrative review. Lung cancer patients with MET-driven tumors, not studied in primary data presented here..
HGF/c-MET signaling axis regulates tumor cell proliferation, epithelial–mesenchymal transition, invasion, metastasis, and therapy resistance in lung cancer. MET signaling shapes the tumor microenvironment, linking tumor-intrinsic oncogenic programs with immune and metabolic regulation. MET activity is spatially heterogeneous within tumors and dynamically influenced by metabolic states, stromal interactions, and co-activated oncogenic pathways.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This review advocates for reconceptualizing MET-driven lung cancer as a context-dependent process requiring spatial, metabolic, and immune profiling rather than genomic assessment alone. It suggests future therapeutic strategies should combine MET inhibition with immunomodulatory or metabolic agents, but this remains a theoretical framework pending clinical validation.
This is a narrative review raising mechanistic questions about MET signaling in lung cancer immunology rather than reporting empirical results from original research.
As stated by the source record.
This review advocates for reconceptualizing MET-driven lung cancer as a context-dependent process requiring spatial, metabolic, and immune profiling rather than genomic assessment alone. It suggests future therapeutic strategies should combine MET inhibition with immunomodulatory or metabolic agents, but this remains a theoretical framework pending clinical validation.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
The hepatocyte growth factor (HGF)/c-MET signaling axis is a central oncogenic driver in lung cancer, regulating tumor cell proliferation, epithelial–mesenchymal transition, invasion, metastasis, and therapy resistance. Increasing evidence indicates that MET signaling also appears to shape the tumor microenvironment (TME), linking tumor-intrinsic oncogenic programs with immune and metabolic regulation. Beyond its canonical tumor-promoting functions, MET may also influence tumor–immune interactions in a context-dependent manner. MET activity is spatially heterogeneous within tumors and dynamically influenced by metabolic states, stromal interactions, and co-activated oncogenic pathways. Through modulation of glycolytic reprogramming, lactate accumulation, adenosine signaling, immune checkpoint expression, and CAF-mediated microdomains, MET may contribute to the formation of localized immunosuppressive niches that facilitate immune evasion and therapeutic resistance. Emerging spatial transcriptomic analyses, single-cell profiling, and integrative metabolic assessments suggest that functional MET dependency cannot be fully captured by static genomic alterations alone. Instead, multidimensional biomarker frameworks incorporating spatial, metabolic, and immune parameters may better define biologically coherent MET-driven tumor states and inform therapeutic selection. Collectively, these insights support moving beyond a purely gene-centric view of MET targeting toward context-aware therapeutic strategies. Combinations of MET inhibition with immunomodulatory or metabolic interventions may help overcome spatially confined immune suppression and resistance mechanisms in MET-driven lung cancer.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.